Evidence map›Paper›PMID 41700643›Full record

ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2026

Efficacy of abrocitinib and dupilumab in itch-dominant atopic dermatitis: An analysis of 2 trials.

Jonathan I Silverberg, Marjolein de Bruin-Weller, Javier Ortiz de Frutos, Juan Francisco Silvestre, Brian Esparza, Daniela E Myers, Pinaki Biswas, Irene Hernández-Martín, Erman Güler, Marina Mikheil and 1 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the European Academy of Dermatology and Venereology : JEADV, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jonathan I SilverbergThe George Washington School of Medicine and Health Sciences, Washington, DC, USA.ORCID https://orcid.org/0000-0003-3686-7805
Marjolein de Bruin-WellerNational Expertise Center for Atopic Dermatitis, University Medical Center, Utrecht, Netherlands.
Javier Ortiz de FrutosHospital Universitario 12 de Octubre, Madrid, Spain.
Juan Francisco SilvestreHospital General Universitario Dr Balmis-ISABIAL, Alicante, Spain.ORCID https://orcid.org/0000-0002-8532-6338
Brian EsparzaPfizer Inc., Collegeville, Pennsylvania, USA.
Daniela E MyersPfizer Inc., New York, New York, USA.
Pinaki BiswasPfizer Inc., New York, New York, USA.
Irene Hernández-MartínPfizer S.L.U, Madrid, Spain.
Erman GülerPfizer Inc., Istanbul, Turkey.
Marina MikheilPfizer Inc., Collegeville, Pennsylvania, USA.
Raj ChovatiyaChicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois, USA.ORCID https://orcid.org/0000-0001-6510-399X

Funding

Pfizer Inc.
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

atopic dermatitisbiologicseczemapruritus

Identifiers

PMID41700643
PMCPMC13308663

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.